Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for bluebird bio, Inc. (BLUE : NSDQ)

• Company Description    bluebird bio, Inc. is a clinical-stage biotechnology that is focused on developing gene therapies for severe genetic diseases and cancer. The company has developed a deep pipeline using lentiviral-based gene therapies, T-cell immunotherapy expertise, and gene editing capabilities to treat severe genetic diseases as well as cancer.?The pipeline for severe genetic diseases includes betibeglogene autotemcel (beti-cel) for the treatment of transfusion-dependent ?-thalassemia (TDT). Number of Employees: 518

• Price / Volume Information    Yesterday's Closing Price: $3.27 Daily Weekly Monthly 20 Day Moving Average: 2,479,301 shares Shares Outstanding: 71.45 (millions) Market Capitalization: $233.65 (millions) Beta: 1.63 52 Week High: $23.87 52 Week Low: $3.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.45% -8.16% 12 Week -47.00% -41.74% Year To Date -67.27% -59.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 BINNEY STREET - CAMBRIDGE,MA 02142 USA ph: 339-499-9300 fax: - investor@bluebirdbio.com http://www.bluebirdbio.com

• General Corporate Information    Officers Andrew Obenshain - ChiefExecutiveOfficer;President Gina Consylman - Chief Financial Officer Jessica Whitten - Vice President; Global Controller and Chief Accoun Mark Vachon - Director John O. Agwunobi - Director Peer Information bluebird bio, Inc. (CORR.) bluebird bio, Inc. (RSPI) bluebird bio, Inc. (CGXP) bluebird bio, Inc. (BGEN) bluebird bio, Inc. (GTBP) bluebird bio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09609G100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 71.45 Most Recent Split Date: (:1) Beta: 1.63 Market Capitalization: $233.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.97 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 38.16% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.89 Price/Cash Flow: - Price / Sales: 6.93 EPS Growth vs. Year Ago Period: 45.93% vs. Previous Quarter: 8.79% Sales Growth vs. Year Ago Period: -84.80% vs. Previous Quarter: 21.11% ROE 03/31/22 - -111.73 12/31/21 - -90.96 09/30/21 - -76.93 ROA 03/31/22 - -71.80 12/31/21 - -62.08 09/30/21 - -54.62 Current Ratio 03/31/22 - 1.78 12/31/21 - 2.20 09/30/21 - 3.12 Quick Ratio 03/31/22 - 1.78 12/31/21 - 2.20 09/30/21 - 3.12 Operating Margin 03/31/22 - -2,066.08 12/31/21 - -1,750.71 09/30/21 - -1,581.07 Net Margin 03/31/22 - -2,183.15 12/31/21 - -1,839.27 09/30/21 - -1,610.78 Pre-Tax Margin 03/31/22 - -1,670.90 12/31/21 - -15,357.18 09/30/21 - -1,502.56 Book Value 03/31/22 - 3.68 12/31/21 - 5.34 09/30/21 - 12.88 Inventory Turnover 03/31/22 - 13.06 12/31/21 - 4.80 09/30/21 - 3.10 Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©